SARS-CoV-2 Variant Testing

摘要 欧盟委员会批准的新出现的SARS-CoV-2疫苗提供的强大保护代表着新冠肺炎疫苗开发的一个关键里程碑。然而，变种的出现再次引发了人们对目前批准的疫苗保护效力的担忧，这些疫苗对某些变种失去了中和效力。然而，新出现的数据表明，抗体的功能，而不是中和，在接种疫苗后早期出现，即使失去中和也仍然存在，可能有助于预防疾病。因此，在这里，我们的目标是描述疫苗诱导抗体的VOC特异性Fc效应功能的广度在疫苗平台上的进化。具体地说，我们的目标是比较接种后几天的亚类、同种类型、Fc受体结合、补体沉积功能、细胞毒性、吞噬细胞活性、脱颗粒和粘液捕获。这些数据将与Novavax(&Medicago)和强生的突破性感染病例进行比较。

Abstract The robust protection conferred by emerging EUA approved SARS-CoV-2 vaccines represents a critical milestone in COVID-19 vaccine development. However, the emergence of variants has inspired renewed concern related to the protective efficacy of currently approved vaccines, which lose neutralizing potency against some variants. However, emerging data suggest that antibody functions, beyond neutralization, that emerge early after vaccination and that persist even with a loss of neutralization, may contribute to protection from disease. Thus, here we aim to profile the evolution of the breadth of the VOC-specific Fc-effector functions of vaccine induced antibodies across vaccine platforms. Specifically, we aim to profile the subclass, isotypes, Fc-receptor binding, complement depositing function, cellular cytotoxicity, opsinophagocytic activity, degranulation, and mucus trapping days after vaccination compared to convalescent individuals. These data will be compared to breakthrough infection cases from Novavax (& Medicago) and J&J.